RxDoctor Payments Data

Alexandra Joseph, MD

Cardiovascular Disease · Venice, FLNPI 1366732414

Payments from drug & device makers

$3,996in general payments, 2019–2025

Across 93 payments — averaging $42.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • AstraZeneca$334
  • Novartis$218
  • Johnson & Johnson$138
  • Boston Scientific$137
  • Regeneron Healthcare Solutions, Inc.$130
  • plus $532 from 9 others

What the payments were for

  • Travel & lodging$1,85746%
  • Food & beverage$1,91948%
  • Education$2206%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,996 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$90,571
Medicare patients
337
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$103,637
EntrestoSacubitril/Valsartan63$71,093
XareltoRivaroxaban24$30,331
Ranolazine ErRanolazine66$6,575
Metoprolol Succinate303$3,174
Prasugrel Hcl15$1,689
ClopidogrelClopidogrel Bisulfate117$1,564
Atorvastatin Calcium171$1,442
Rosuvastatin Calcium69$1,140
Amlodipine Besylate113$963
Carvedilol106$960
Valsartan21$735
Isosorbide Mononitrate ErIsosorbide Mononitrate38$470
Furosemide94$451
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$103,63788 claims
NovartisEntresto$218$71,09363 claims
Johnson & JohnsonXarelto$138$30,33124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →